Investigation of Presence of O25b-ST131 Clone and in vitro Efficacy of Temocillin in Escherichia coli Isolates

Abstract

Escherichia coli ST131 isolates associated with fluoroquinolone and cephalosporin resistance have increased in the last ten years. This increase leads to the emergence of multidrug-resistant E. coli isolates and failure in the treatment of urinary tract infections. Carbapenem and fosfomycin antibiotics are among the limited treatment options for E. coli ST131 isolates. However, the increasing use of these antibiotics leads to the spread of carbapenem and fosfomycin resistance genes and increased resistance. Increasing antimicrobial resistance in Gram-negative bacteria and the scarcity of new antimicrobials have brought old antimicrobials to the agenda again. Temocillin is an old antimicrobial that has significant advantages. This agent may be an alternative to carbapenems in the treatment of serious Enterobacterales infections, such as systemic urinary tract infections. This study investigated the presence of the O25b-ST131 clone in fluoroquinolone-resistant E. coli isolates and the resistance to temocillin in these isolates. In our study, it was determined that 40.8% of the isolates were E. coli O25b-ST131 isolates. Given that all the isolates are fluoroquinolone-resistant E. coli, a high prevalence of O25b-ST131 is expected. The findings of the antibiotic resistance tests revealed that all isolates had low levels of carbapenem and fosfomycin resistance (2.04% and 3.06, respectively). Additionally, there were no significant differences in resistance between E. coli ST131 isolates and other isolates. Temocillin is an antimicrobial agent widely used in many European countries, particularly for the treatment of carbapenem-resistant E. coli infections. High rates of temocillin resistance (50%) were observed in our study, although this agent has not yet been used in our country. These high resistance rates could be related to cross-antibiotic resistance.

Keywords

• Uropathogenic E. coli
• E. coli ST-131
• temocillin

References

1. 1. Uslu M, Bağcıoğlu M, Tekdoğan ÜY, Kocaaslan R, Çeçen K. Kars Bölgesindeki İdrar Yolu Enfeksiyonlarının Epidemiyolojisi ve Antibiyotik Dirençleri. Kafkas Tıp Bil Derg. 2019; 9(2): 90-96.
2. 2. Tüzün Özdemir S, Akyol A. Böbrek Enfeksiyon Hastalıkları. In: Ünsal Avdal E, editor. Nefrolojide Güncel Kanıt Temelli Yaklaşımlar. Ankara: Türkiye Klinikleri; 2022, p.5-11.
3. 3. Larramendy S, Deglaire V, Dusollier P, Fournier JP, Caillon J, Beaudeau F, et al. Risk factors of extended-spectrum beta-lactamases-producing Escherichia coli community acquired urinary tract infections: a systematic review. Infect Drug Resist, 2020: 13; 3945-55.
4. 4. Pitout JD. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev Anti Infect Ther. 2012; 10(10): 1165-76.
5. 5. Cortés-Cortés G, Lozano-Zarain P, Torres C, Alonso CA, Ríos-Torres AM, Castañeda M, et al. Extended-spectrum β-lactamase-producing Escherichia coli isolated from healthy humans in Mexico, including subclone ST131-B2-O25: H4-H30-Rx. J Glob Antimicrob Resist. 2017; 9: 130-134.
6. 6. Çizmeci Z, Otlu B, Aktaş E, Ördekçi S, Açıkgöz Ö, Güleç N. Investigation of High-Risk ST131 Clone in ESBL-Producing Escherichia coli Isolates Isolated from Urine and Non-urinary Clinical Specimens with MALDI-TOF MS and Real Time PCR. Mikrobiyol Bul. 2018; 52(1): 13-22.
7. 7. Zhong YM, Liu WE, Meng Q, Li Y. Escherichia coli O25b-ST131 and O16-ST131 causing urinary tract infection in women in Changsha, China: molecular epidemiology and clinical characteristics. Infect Drug Resist. 2019; 12: 2693-2702.
8. 8. Çizmeci Z, Otlu B, Aktaş E, Ördekçi S, Açıkgöz Ö, Güleç N. İdrar ve idrar dışı klinik örneklerden izole edilen gsbl üreten Escherichia coli izolatlarında yüksek riskli ST131 klonunun MALDI-TOF MS ve gerçek zamanlı PCR ile araştırılması. Mikrobiyol Bul. 2018; 52(1): 13-22.

9. 9. Gürpınar Ö. Kinolon dirençli ve duyarlı invaziv Escherichia coli kan izolatlarında ST131/H30 klon/subklonunun virülans ile ilişkisi [dissertation]. Ankara: Hacettepe University; 2018.
10. 10. Assimacopoulos A, Johnston B, Clabots C, Johnson JR. Post-prostate biopsy infection with Escherichia coli ST131 leading to epididymo-orchitis and meningitis caused by Gram-negative bacilli. J Clin Microbiol. 2012; 50(12): 4157-9.
11. 11. Adams-Sapper S, Diep BA, Perdreau-Remington F, Riley LW. Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother. 2013; 57(1): 490-497.
12. 12. Lopez-Cerero L, Navarro MD, Bellido M, Martin-Pena A, Vinas L, Cisneros JM, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131:risk factors and clinical implications. J Antimicrobial Chemother. 2014; 69(3): 809-814.
13. 13. Williamson DA, Freeman JT, Porter S, Roberts S, Wiles S, Paterson DL, et al. Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. J Antimicrob Chemother. 2013; 68(12): 2898-2906.
14. 14. van der Donk CF, van de Bovenkamp JH, De Brauwer EI, De Mol P, Feldhoff K-H, Kalka-Moll WM, et al. Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine. PLoS One. 2012; 7(10): e47707.
15. 15. Johnson TJ, Logue CM, Johnson JR, Kuskowski MA, Sherwood JS, Barnes HJ, et al. Associations between multidrug resistance, plasmid content, and virulence potential among extraintestinal pathogenic and commensal Escherichia coli from humans and poultry. Foodborne Pathog Dis. 2012; 9(1): 37-46.
16. 16. Christiansen N, Nielsen L, Jakobsen L, Stegger M, Hansen LH, Frimodt-Møller N. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country. Microb Drug Resist. 2011; 17(3): 395-406.
17. 17. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012; 40(l): S37-43.
18. 18. Johnson JR, Menard ME, Lauderdale T-L, Kosmidis C, Gordon D, Collignon P, et al. Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007. Emerg Infect Dis. 2011; 17(11): 2001-9. 19. Pitout J. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front Microbiol. 2012; 3: 9.
19. 20. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother. 2009; 63: 243–245.
20. 21. Kuch A, Zieniuk B, Zabicka D, et al. Activity of temocillin against ESBL-, AmpC-, and/or KPC producing Enterobacterales isolated in Poland. Eur J Clin Microbiol Infect Dis. 2020; 39(6): 1185-1191.
21. 22. Alexandre K, Fantin B. Pharmacokinetics and pharmacodynamics of temocillin. Clin Pharmacokinet. 2018; 57: 287–96.
22. 23. Alexandre K, Réveillon-Istin M, Fabre R, Delbos V, Etienne M, Pestel-Caron M, Dahyot S, Caron F. Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods. J Antimicrob Chemother. 2018; 73(7): 1848-1853.
23. 24. Tanrıverdi A. Genişlemiş spektrumlu beta-laktamaz üreten escherichia coli ve klebsiella SPP. izolatlarının ertapenem, meropenem, imipenem, kolistin, fosfomisin ve temosilin'e fenotipik duyarlılığının belirlenmesi ve direnç genlerinin in house PCR yöntemiyle araştırılması [Doctoral dissertation]. Adıyaman: Adıyaman Üniversitesi; 2021.
24. 25. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother. 2009; 64(2): 274-7.
25. 26. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables and dosages Version 12.0 [Internet]. 2022 [updated 2022 Jan 1; cited 2022 July 10]. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf
26. 27. Marcus N, Ashkenazi S, Yaari A, Samra Z, Livni G. Non-Escherichia coli versus Escherichia coli community-acquired urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and outcome. J Pediatr Infect Dis. 2020; 24(7): 581-585.
27. 28. Wu J, Lan F, Lu Y, He Q, Li B. Molecular characteristics of ST1193 clone among phylogenetic group B2 non-ST131 fluoroquinolone-resistant Escherichia coli. Front Microbiol. 2017; 8: 2294.
28. 29. Banerjee R, Johnston B, Lohse C, Chattopadhyay S, Tchesnokova V, Sokurenko EV, et al. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother. 2013; 57(12): 5912-7.
29. 30. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev. 2014; 27(3): 543–574.
30. 31. Demirci M, Ünlü Ö, İstanbullu Tosun A. Detection of O25b-ST131 clone, CTX-M-1 and CTX-M-15 genes via real-time PCR in Escherichia coli strains in patients with UTIs obtained from a university hospital in Istanbul. J Infect Public Health. 2019;1 2(5): 640-644.
31. 32. Namaei MH, Yousefi M, Ziaee M, Salehabadi A, Ghannadkafi M, Amini E, Askari P. First Report of Prevalence of CTX-M-15-Producing Escherichia coli O25b/ST131 from Iran. Microb Drug Resist. 2017; 23(7): 879-884.
32. 33. Fukushima Y, Sato T, Tsukamoto N, Nakajima C, Suzuki Y, Takahashi S, et al. Clonal/subclonal changes and accumulation of CTX-M-type β-lactamase genes in fluoroquinolone-resistant Escherichia coli ST131 and ST1193 strains isolated during the past 12 years, Japan. J Glob Antimicrob Resist. 2021; 27: 150-155.
33. 34. Ludden C, Cormican M, Vellinga A, Johnson JR, Austin B, Morris D. Colonisation with ESBL-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant enterococci, and meticillin-resistant Staphylococcus aureus in a long-term care facility over one year. BMC Infect Dis. 2015; 15: 168.
34. 35. Brodrick HJ, Raven KE, Kallonen T, Jamrozy D, Blane B, Brown NM, et al. Longitudinal genomic surveillance of multidrug-resistant Escherichia coli carriage in a long-term care facility in the United Kingdom. Genome Med. 2017; 9(1): 70.
35. 36. Burgess MJ, Johnson JR, Porter SB, Johnston B, Clabots C, Lahr BD, et al., editors. Long-term care facilities are reservoirs for antimicrobial-resistant sequence type 131 Escherichia coli. Open Forum Infect Dis. 2015; 2(1): ofv011.
36. 37. Pulcini C, Bush K, Craig WA, Frimodt-Møller N, Grayson ML, Mouton JW et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis. 2012; 54(2): 268–74.
37. 38. Fuchs PC, Barry AL, Thornsberry C, Jones RN. Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol. 1985; 4: 30–3.
38. 39. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. Document M100-S20-U, 2010. CLSI, Wayne, PA.
39. 40. British Society for Antimicrobial Chemotherapy (BSAC). Methods for Antimicrobial Susceptibility Testing. https://bsac.org.uk/wp-content/uploads/2012/02/Version-12-Apr-2013_final.pdf.
40. 41. Comité de l’antibiogramme de la Société Française de Microbiologie (CA-SFM). Comité de l’Antibiogramme de la Société Française de Microbiologie. Recommandations 2019, V.1.0 Janvier. https://www.sfmmicrobiologie.org/wp-content/uploads/2019/02/CASFM2019_V1.0.pdf.
41. 42. Duployez C, Loïez C, Cattoen C, Wallet F, Vachée A. In vitro activity of temocillin against extended-spectrumbeta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France. Med Mal Infect. 2019; 49(1): 47-53.
42. 43. Chen YT, Ahmad Murad K, Ng LS, Seah JT, Park JJ, Tan TY. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia coli and Klebsiella pneumoniae from Urinary Tract Infections. Ann Acad Med Singap. 2016; 45(6): 245-50.
43. 44. Seo MR, Kim SJ, Kim Y, Kim J, Choi TY, Kang JO, Wie SH, Ki M, Cho YK, Lim SK, Lee JS, Kwon KT, Lee H, Cheong HJ, Park DW, Ryu SY, Chung MH, Pai H. Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea. J Korean Med Sci. 2014; 29(8): 1178-81.
44. 45. Ocak F, Cesur S, Kınıklı S. Genişlemiş spektrumlu beta-laktamaz üreten E. coli izolatlarının çeşitli antibiyotiklere duyarlılıklarının belirlenmesi. Turk J Clin Lab. 2019; 10(3): 384-387.